Immutep Ltd
NASDAQ:IMMP

Watchlist Manager
Immutep Ltd Logo
Immutep Ltd
NASDAQ:IMMP
Watchlist
Price: 2.95 USD 3.15% Market Closed
Market Cap: 428.5m USD

Net Margin
Immutep Ltd

-102 220%
Current
-40 406%
Average
-6.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-102 220%
=
Net Income
-61.4m
/
Revenue
60.1k

Net Margin Across Competitors

Country Company Market Cap Net
Margin
AU
Immutep Ltd
ASX:IMM
620.7m AUD
-102 220%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-21 040%
US
Abbvie Inc
NYSE:ABBV
388.8B USD
4%
US
Amgen Inc
NASDAQ:AMGN
172.1B USD
19%
US
Gilead Sciences Inc
NASDAQ:GILD
145.5B USD
28%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
113.2B USD
31%
US
Epizyme Inc
F:EPE
94.1B EUR
-392%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
80B USD
32%
AU
CSL Ltd
ASX:CSL
83.5B AUD
19%
NL
argenx SE
XBRU:ARGX
44.1B EUR
43%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
51.4B USD
1%
No Stocks Found

Immutep Ltd
Glance View

Market Cap
428.5m USD
Industry
Biotechnology

Immutep Ltd. is a biotechnology company, which engages in the research and development of immunotherapeutic treatments for cancer and autoimmune diseases. The company is headquartered in Sydney, New South Wales. The firm is engaged in the development of LAG-3 immunotherapeutic products for cancer and autoimmune disease. The firm has four product candidates based on the LAG-3 immune control mechanism. Its lead product candidate, eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein, which is in later-stage clinical development for the treatment of cancer. Its second product candidate (IMP761) is in pre-clinical development for the treatment of autoimmune disease. The Company’s two licensed product candidates include Antagonist AB (LAG525) and Depleting AB (GSK‘781). The Company’s operates through its subsidiaries, which includes Immutep USA Inc, PRR Middle East FZ LLC, Immutep GmbH, Immutep Australia Pty Ltd, Immutep IP Pty Ltd and Immutep S.A.S.

IMMP Intrinsic Value
21.63 USD
Undervaluation 86%
Intrinsic Value
Price
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-102 220%
=
Net Income
-61.4m
/
Revenue
60.1k
What is the Net Margin of Immutep Ltd?

Based on Immutep Ltd's most recent financial statements, the company has Net Margin of -102 220%.

Back to Top